SpliceBio has closed a Series B financing round, raising $135m for the clinical development of SB-007 for Stargardt disease.

For decades, the dominant treatment approaches for substance use disorder have centered around identifying past deficits and unpacking trauma. SFT offers a compelling alternative.

Since the approval of Luxturna, there has been a wave of gene therapies advancing in clinical trials to treat genetic vision ...